VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

SABCS 2022 | New directions in immunotherapy for improving outcomes in TNBC

Heather McArthur, MD, MPH, UT Southwestern Medical Center, Dallas, TX, discusses new directions in immunotherapy for improving outcomes in triple-negative breast cancer (TNBC), including the development of better drug for patients who are high-risk and who have residual disease at the time of surgery after receiving the the Phase III KEYNOTE-522 (NCT03036488) regimen of pembrolizumab with neoadjuvant chemotherapy, as well as de-escalation of treatment for patients who are low-risk. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript (edited for clarity)

I would say that there are two big themes in that space. One is trying to understand how to give more or better drugs to those who are at particularly high-risk. So the cooperative groups are attending to those questions. They’re going to require very large studies to ask and answer those questions. So for patient- who receive the KEYNOTE-522 regimen, but have residual disease at the time of surgery, those patients are at extremely high risk of developing a distant recurrence...

I would say that there are two big themes in that space. One is trying to understand how to give more or better drugs to those who are at particularly high-risk. So the cooperative groups are attending to those questions. They’re going to require very large studies to ask and answer those questions. So for patient- who receive the KEYNOTE-522 regimen, but have residual disease at the time of surgery, those patients are at extremely high risk of developing a distant recurrence.

And so the cooperative groups are going to look at combining an antibody-drug conjugate together with pembrolizumab versus the standard of care pembrolizumab. So escalation of therapy for those who are at highest risk. And then on the flip side is de-escalation of therapy for those who are going to have great outcomes and maybe require less therapy. So those are the two big themes for study in that space.

Read more...

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter